Amylyx Drug Slows ALS Progression, Filings Imminent

Amylyx Pharmaceuticals, Inc. had just three employees in early 2019, including co-CEOs/co-founders Justin Klee and Josh Cohen, and now the company is ready to submit its drug for regulatory approvals based on the Phase II/III CENTAUR clinical trial in amyotrophic lateral sclerosis (ALS), which showed slower disease progression for ALS patients treated with AMX0035 versus those who received a placebo.

Cambridge, MA-based Amylyx is a small private company that has raised just $75m to date from venture capital investors and disease foundations to support its trials for AMX0035 in ALS and Alzheimer’s disease, but it has grown to 21 employees, including executives with experience commercializing new drugs